Local, Sustained, and Targeted Co-Delivery of MEK Inhibitor and Doxorubicin Inhibits Tumor Progression in E-Cadherin-Positive Breast Cancer

Local, Sustained, and Targeted Co-Delivery of MEK Inhibitor and Doxorubicin Inhibits Tumor Progression in E-Cadherin-Positive Breast Cancer

Effectively utilizing MEK inhibitors in the clinic remains challenging due to off-target toxicity and lack of predictive biomarkers. Recent findings propose E-cadherin, a breast cancer diagnostic indicator, as a predictor of MEK inhibitor success. To address MEK inhibitor toxicity, traditional metho...

Full description

Bibliographic Details
Main Authors: Paul M. Kuhn, Gabriella C. Russo, Ashleigh J. Crawford, Aditya Venkatraman, Nanlan Yang, Bartholomew A. Starich, Zachary Schneiderman, Pei-Hsun Wu, Thi Vo, Denis Wirtz, Efrosini Kokkoli
Format: Article
Language:English
Published: MDPI AG 2024-07-01
Series:Pharmaceutics
Subjects:
MEK inhibitor
doxorubicin
E-cadherin positive breast cancer
hydrogel
PR_b-targeted liposomes
Online Access:https://www.mdpi.com/1999-4923/16/8/981

Internet

https://www.mdpi.com/1999-4923/16/8/981

Similar Items